# Latterell Venture Partners

> Latterell Venture Partners is a VC fund backing Health Care and Biotechnology. See 35 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 35
- Last investment: Nov 2020
- Lead investor: 11%
- Last updated: Aug 2026
- Website: http://www.lvpcapital.com

Latterell Venture Partners is a venture capital firm specialized in startups and early stage healthcare companies, including biotechnology, pharmaceutical, research instrument, biomaterial, medical device, healthcare IT, and diagnostic ventures.The firm invests in early stage healthcare companies with innovative technologies, large marketopportunities, and passionate entrepreneurs. It offers a collection of venture capital, entrepreneurial, technical, clinical, and collaborative skills enabling entrepreneurs to create successful startups.Founded in 2001, Latterell Venture Partners is based in San Francisco, California.

## Contacts

5 contacts available for Latterell Venture Partners. Shizune tracks 6 team members at Latterell Venture Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/latterell-venture-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 12 | 34% |
| Biotechnology | 12 | 34% |
| Medical Device | 6 | 17% |
| Therapeutics | 5 | 14% |
| Pharmaceutical | 5 | 14% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 11 | 31% |
| Series C | 7 | 20% |
| Series A | 5 | 14% |
| Funding Round | 2 | 6% |
| Series D | 1 | 3% |

9 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bob Curry | Partner | 0 | — |
| Dalton Einhorn | Team Member | 0 | — |
| James Woody | General Partner | 7 | — |
| Ken Widder | General Partner | 3 | — |
| Pat Latterell | Founder | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Viracta Therapeutics | Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application ofthis inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers. | $40M | Series E | Nov 30, 2020 |  |
| Pulmonx | Pulmonx is the global leader in interventional procedures for the treatment of COPD. It develops and markets non-surgical technologies for the assessment and treatment of patients with severe emphysema, a progressive and life-threatening form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), theChartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The technology is supported by a compelling body of clinical evidence including over 100 published scientific articles regarding the clinical benefits of Zephyr Valves. FDA granted the Zephyr Valve a ‘breakthrough device’ designation, and in June 2018 Pulmonx received FDA pre-market approval to commercialize our Zephyr Valve. The Zephyr Valve is now commercially available and physicians in more than 25 countries around the world routinely use the Zephyr Valves to improve the lives of patients with severe emphysema, with over 76,000 valves used to treat more than 19,000 patients worldwide to date. | $65M | Series G | May 09, 2019 |  |
| Neuraltus Pharmaceuticals | Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases. Neuraltus has three clinical-stage programs in its development pipeline, including potential treatments forAmyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease), Parkinson's disease and dyskinesias associated with the treatment of Parkinson's disease, Alzheimer's disease, and Multiple Sclerosis, as well as lysosomal storage disorders such as Fabry's disease and Gaucher's disease. Each of Neuraltus' clinical-stage programs is advancing novel drug molecules that represent new, first-in-class approaches to treating the Company's target disease indications.Neuraltus began operations in 2009 based on a broadly enabling technology portfolio and intellectual property assembled by the company founders, Ari Azhir, PhD, Neuraltus' Chief Operating Officer; Michael McGrath, MD, PhD, Professor of Laboratory Medicine at the University of California, San Francisco; and Edgar Engleman, MD, Professor of Medicine and Pathology at Stanford University School of Medicine. In March 2009 Neuraltus closed a $17M Series A financing with leading venture groups Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners | $14.9M |  | May 24, 2016 |  |
| PerceptiMed | PerceptiMed’s groundbreaking VeriFill™ technology reduces the margin of human error in prescription pill dispensing within retail pharmacies, long-term care facilities and hospitals. Its IdentRx™suite of medication verification and dispensing products are fast, accurate and cost-effective -- providing 100% verification of drug, dosage andmanufacturer for every pill, every time. | $5.4M | Series A | Mar 27, 2015 |  |
| Naurex | Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs),which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators. | $80M | Series C | Dec 03, 2014 |  |
| Transcend Medical | Transcend Medical is focused on the development of medical devices for the treatment of glaucoma, a cause of adult irreversible blindness. It is estimated that nearly four million people in the US and over 60 million worldwide are afflicted with the disease today and the numbers are expected to grow to nearly six million in the US, and to over 70million worldwide by the year 2015.In 2005, Transcend Medical was the first company to spin out of ForSight Labs, an incubator solely focused on ophthalmic innovations. Transcend Medical was granted CE mark for the CyPass Micro-Stent® in 2008, and is being evaluated in several clinical studies in the US and abroad, including the COMPASS multi-center clinical trial. | $29M | Series C | Apr 02, 2014 |  |
| Naurex | Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs),which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators. | $38M | Series B | Dec 17, 2012 |  |
| Neuraltus Pharmaceuticals | Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases. Neuraltus has three clinical-stage programs in its development pipeline, including potential treatments forAmyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease), Parkinson's disease and dyskinesias associated with the treatment of Parkinson's disease, Alzheimer's disease, and Multiple Sclerosis, as well as lysosomal storage disorders such as Fabry's disease and Gaucher's disease. Each of Neuraltus' clinical-stage programs is advancing novel drug molecules that represent new, first-in-class approaches to treating the Company's target disease indications.Neuraltus began operations in 2009 based on a broadly enabling technology portfolio and intellectual property assembled by the company founders, Ari Azhir, PhD, Neuraltus' Chief Operating Officer; Michael McGrath, MD, PhD, Professor of Laboratory Medicine at the University of California, San Francisco; and Edgar Engleman, MD, Professor of Medicine and Pathology at Stanford University School of Medicine. In March 2009 Neuraltus closed a $17M Series A financing with leading venture groups Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners | $1.5M |  | Apr 01, 2012 |  |
| Neuraltus Pharmaceuticals | Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases. Neuraltus has three clinical-stage programs in its development pipeline, including potential treatments forAmyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease), Parkinson's disease and dyskinesias associated with the treatment of Parkinson's disease, Alzheimer's disease, and Multiple Sclerosis, as well as lysosomal storage disorders such as Fabry's disease and Gaucher's disease. Each of Neuraltus' clinical-stage programs is advancing novel drug molecules that represent new, first-in-class approaches to treating the Company's target disease indications.Neuraltus began operations in 2009 based on a broadly enabling technology portfolio and intellectual property assembled by the company founders, Ari Azhir, PhD, Neuraltus' Chief Operating Officer; Michael McGrath, MD, PhD, Professor of Laboratory Medicine at the University of California, San Francisco; and Edgar Engleman, MD, Professor of Medicine and Pathology at Stanford University School of Medicine. In March 2009 Neuraltus closed a $17M Series A financing with leading venture groups Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners | $9.6M | Series B | Jan 31, 2012 |  |
| Pulmonx | Pulmonx is the global leader in interventional procedures for the treatment of COPD. It develops and markets non-surgical technologies for the assessment and treatment of patients with severe emphysema, a progressive and life-threatening form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), theChartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The technology is supported by a compelling body of clinical evidence including over 100 published scientific articles regarding the clinical benefits of Zephyr Valves. FDA granted the Zephyr Valve a ‘breakthrough device’ designation, and in June 2018 Pulmonx received FDA pre-market approval to commercialize our Zephyr Valve. The Zephyr Valve is now commercially available and physicians in more than 25 countries around the world routinely use the Zephyr Valves to improve the lives of patients with severe emphysema, with over 76,000 valves used to treat more than 19,000 patients worldwide to date. | $10M | Private Equity | Jan 31, 2012 |  |

10 of 35 investments shown.

## Co-investors
- [The Vertical Group](https://shizune.co/investors/profile/the-vertical-group) — VC Fund, 12 deals together
- [Adams Street Partners](https://shizune.co/investors/profile/adams-street-partners) — VC Fund, 8 deals together
- [DeNovo Ventures](https://shizune.co/investors/profile/denovo-ventures) — VC Fund, 6 deals together
- [Morgenthaler Ventures](https://shizune.co/investors/profile/morgenthaler-ventures) — VC Fund, 6 deals together
- [HLM Venture Partners](https://shizune.co/investors/profile/hlm-venture-partners) — VC Fund, 5 deals together
- [U.S. Venture Partners](https://shizune.co/investors/profile/us-venture-partners) — VC Fund, 5 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Latterell Venture Partners invest in?

Latterell Venture Partners invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B and Series C stage. Most of the 35 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Latterell Venture Partners?

Public channels for Latterell Venture Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Latterell Venture Partners?

The team at Latterell Venture Partners includes Bob Curry (Partner), Dalton Einhorn (Team Member) and James Woody (General Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co